Lipid-lowering nutraceuticals in clinical practice: Position paper from an International Lipid Expert Panel

Cicero, A. F. G. and Colletti, A. and Bajraktari, G. and Descamps, O. and Djuric, D. M. and Ezhov, M. and Fras, Z. and Katsiki, N. and Langlois, M. and Latkovskis, G. and Panagiotakos, D. B. and Paragh, G. and Mikhailidis, D. P. and Mitchenko, O. and Paulweber, B. and Pella, D. and Pitsavos, C. and Reiner, Z. and Ray, K. K. and Rizzo, M. and Sahebkar, A. and Serban, M. C. and Sperling, L. S. and Toth, P. P. and Vinereanu, D. and Vrablík, M. and Wong, N. D. and Banach, M. and on behalf of the International Lipid Expert, Panel (2017) Lipid-lowering nutraceuticals in clinical practice: Position paper from an International Lipid Expert Panel. Nutrition Reviews, 75 (9). pp. 731-767.

[img] Text
Lipid lowering nutraceuticals in clinical practice Position paper from an International Lipid Expert Panel.pdf

Download (875kB)

Abstract

In recent years, there has been growing interest in the possible use of nutraceuticals to improve and optimize dyslipidemia control and therapy. Based on the data from available studies, nutraceuticals might help patients obtain theraputic lipid goals and reduce cardiovascular residual risk. Some nutraceuticals have essential lipidlowering properties confirmed in studies; some might also have possible positive effects on nonlipid cardiovascular risk factors and have been shown to improve early markers of vascular health such as endothelial function and pulse wave velocity. However, the clinical evidence supporting the use of a single lipid-lowering nutraceutical or a combination of them is largely variable and, for many of the nutraceuticals, the evidence is very limited and, therefore, often debatable. The purpose of this position paper is to provide consensus-based recommendations for the optimal use of lipid-lowering nutraceuticals to manage dyslipidemia in patients who are still not on statin therapy, patients who are on statin or combination therapy but have not achieved lipid goals, and patients with statin intolerance. This statement is intended for physicians and other healthcare professionals engaged in the diagnosis and management of patients with lipid disorders, especially in the primary care setting. © The Author(s) 2017. Published by Oxford University Press on behalf of the International Life Sciences Institute. All rights reserved.

Item Type: Article
Additional Information: (ILEP) Cited By :83 Export Date: 16 February 2020 CODEN: NUREA Correspondence Address: Cicero, A.F.G.; Atherosclerosis Research Center, Via Albertoni, 15, Italy; email: arrigo.cicero@unibo.it
Uncontrolled Keywords: Dyslipidemia Lipid Nutraceuticals Position paper Recommendations alpha tocopherol anthocyanin antilipemic agent berberine beta glucan carnitine chitosan cholestin conjugated linoleic acid curcumin Cynara acolymus extract gamma oryzanol hydroxymethylglutaryl coenzyme A reductase inhibitor ispagula low density lipoprotein cholesterol mannan nutraceutical omega 3 fatty acid pantethine phycocyanin phytosterol policosanol probiotic agent silymarin sinecatechins soybean protein stanozolol unclassified drug unindexed drug xuezhikang high density lipoprotein cholesterol phytochemical triacylglycerol unsaturated fatty acid artichoke Article cardiovascular disease cardiovascular risk Chlorella Citrus bergania citrus fruit clinical practice dietary fiber drug efficacy drug mechanism drug safety drug tolerability economic aspect endothelium garlic Glycyrrhiza health care personnel human intestine absorption lifestyle modification lupin Momordica charantia nonhuman patient care physician prevalence primary medical care pulse wave randomized controlled trial (topic) risk factor risk reduction Silybum marianum Spirulina blood dietary supplement drug effects drug interaction evidence based medicine lifestyle liver meta analysis (topic) metabolism observational study Cardiovascular Diseases Cholesterol, HDL Cholesterol, LDL Dietary Supplements Drug Interactions Dyslipidemias Evidence-Based Medicine Fatty Acids, Unsaturated Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Intestinal Absorption Life Style Meta-Analysis as Topic Observational Studies as Topic Phytochemicals Probiotics Randomized Controlled Trials as Topic Risk Factors Triglycerides
Subjects: WD Nutrition Disease and metabolic diseases
QU Biochemistry
Divisions: Mashhad University of Medical Sciences
Depositing User: mr lib3 lib3
Date Deposited: 18 May 2020 09:02
Last Modified: 18 May 2020 09:02
URI: http://eprints.mums.ac.ir/id/eprint/16789

Actions (login required)

View Item View Item